Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

The technological innovation is an expansion of the NOBIVAC NXT platform, and a breakthrough achievement against one of the ...

First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...

Factors related to sex and gender can affect therapy outcomes and should not be overlooked in clinical practice or research.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

Ben-Aharon declared financial interests with AstraZeneca, MSD and Merck (invited speaker), and Bristol Myers Squibb and ...

The global Animal Antibacterial and Antibiotics Market is projected to grow from approximately USD 4.9 billion in 2024 to ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S.Food and Drug Administration (FDA) ...

The EMA CHMP has recommended approval of MSD’s KEYTRUDA for two gynaecological cancers: endometrial and cervical.

The Health Sciences Authority (HSA) of Singapore has approved Merck & Co’s Winrevair (sotatercept), for the treatment of ...

EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...